[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638693":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":34,"locations":44,"responsibleParty":62,"collaborators":25,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":25,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":25,"enrollmentInfo":73,"targetDuration":25,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":83,"overallStatus":85,"whyStopped":25,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Stanford University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"LATTICE Radiotherapy","EXPERIMENTAL","Participants receive 5-fraction LATTICE radiotherapy delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.",[13],"Radiation: LATTICE Radiotherapy",{"label":15,"type":16,"description":17,"interventionNames":18},"Standard Radiotherapy","ACTIVE_COMPARATOR","Participants receive standard radiotherapy (25 Gy in 5 fractions)",[19],"Radiation: Standard radiotherapy",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"RADIATION","5-fraction LATTICE radiotherapy delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.",[9],null,{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Standard radiotherapy","Standard radiotherapy delivered to 25 Gy in 5 fractions.",[15],[31],{"name":32,"affiliation":5,"role":33},"Michael Gensheimer, MD","PRINCIPAL_INVESTIGATOR",[35,40],{"name":36,"role":37,"phone":38,"phoneExt":25,"email":39},"Jamie Wang","CONTACT","650-497-4354","jwang97@stanford.edu",{"name":41,"role":37,"phone":42,"phoneExt":25,"email":43},"Camellia Djebroun","650-736-5564","cdjebrou@stanford.edu",[45],{"facility":5,"status":25,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Palo Alto","California","94304","United States","US",{"type":52,"coordinates":53},"Point",[54,55],-122.14302,37.44188,{"lat":55,"lon":54},[58,60,61],{"name":59,"role":37,"phone":38,"phoneExt":25,"email":39},"Jamie Wong",{"name":41,"role":37,"phone":42,"phoneExt":25,"email":43},{"name":32,"role":33,"phone":25,"phoneExt":25,"email":25},{"type":63,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100638693","phase-2-trial-comparing-lattice-radiotherapy-vs-moderately-dose-escalated-palliative-radiation-for-patients-with-metastases-100638693",false,"NCT07594431","Trial Comparing LATTICE Radiotherapy vs Moderately Dose-escalated Palliative Radiation for Patients With Metastases.","A Randomized Phase II Trial Comparing LATTICE Radiotherapy vs Moderately Dose-escalated Palliative Radiation for Patients With Metastases.","80 patients with confirmed metastatic tumor (\\>2.5 cm in short axis) will be enrolled, all ≥ 12 years of age with ECOG ≤ 2. All genders and races will be included.\n\nInclusion Criteria:\n\n* Histologically, cytologically, or radiographically confirmed diagnosis of metastatic cancer\n* One to two metastases in non-brain sites that are amenable to LATTICE radiotherapy: \\>2.5 cm in short axis (dimension on axial imaging that is perpendicular to the longest dimension); bone metastasis can be included if the extraosseous component is \\>2.5 cm in short axis\n* Age ≥12\n* ECOG Performance Status 0-2\n* For patients age 12-16, Lansky Play-Performance score 50-100\n* Negative serum or urine pregnancy test within 2 weeks prior to enrollment of people of childbearing potential\n* All patients and\u002For their parents or legal guardians must sign a written informed consent. For any child less than 18 years of age, assent must also be obtained in addition to parental or legal guardian consent.\n\nExclusion criteria:\n\n* Prior radiation therapy to the tumor to be treated\n* Active pregnancy\n* Diseases that place the patient at high risk of radiation complications including lupus, scleroderma, Li Fraumeni syndrome\n* The tumor to be treated is from a hematologic malignancy such as lymphoma or myeloma","ALL","12 Years",{"count":74,"type":75},80,"ESTIMATED","INTERVENTIONAL",[78],"PHASE2","Unblinded, randomized study of 5-fraction LATTICE radiotherapy (20 Gy with an SIB to 66.7 Gy in 5 fractions) versus moderately dose-escalated palliative radiation (25 Gy in 5 fractions)",[81,82],"Metastases","Metastatic Cancer",[9,84],"Palliative Radiotherapy","NOT_YET_RECRUITING","2026-05-12",{"date":88,"type":89},"2026-05-18","ACTUAL",{"date":91,"type":75},"2026-08",{"date":93,"type":75},"2028-08",{"name":5,"class":6},1]